|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A comparative study of the characteristics of two Coxsackie A virus type 16 strains (genotype B)显示文摘Coxsackie A virus is one of the major pathogens associated with hand, foot and mouth disease (HFMD). The etiological characteristics of Coxsackie A virus type 16 (CA16) are thought to correlate with the pathological process of its infection. Two CA16 strains that were isolated from a severe HFMD patient presented with different plaque forms. This observation, along with biological analysis, indicated that the differences in the strains' biological characteristics, such as proliferation kinetics and immunogenicity, correlate with differences in their pathogenicity toward neonatal mice. Furthermore, these differences are thought to be associated with the sequence of the 5′ non-coding region of the viral genome and the VP1 structural region sequence. The results suggest that the biological and genetic characteristics of the CA16 viral strains are relevant to their pathogenicity. | YANG ErXia ZHAO Heng ZHANG Ying LIU JianSheng LIAO Yun WANG LiChun CUI PingFang YANG LiXian LIU LongDing DONG ChengHong DONG ShaoZhong SHAO CongWen JIANG Li SUN Le LI QiHan | 2012 | Science China(Life Sciences)2012，55，4： | 5 |
| 2 | Transcriptional regulation of the Herpes Simplex Virus 1α-gene by the viral immediate-early protein ICP22 in association with VP16显示文摘Herpes Simplex Virus 1 (HSV1) is capable of inducing two forms of infection in individuals, and the establishment of which type of infection occurs is linked to the transcriptional activation of viral α genes. One of the HSV1 α genes, ICP22, is known to have multiple functions during virus replication, but its distinct roles are still unclear. This study showed that ICP22 functions as a general repressor for certain viral and cellular promoters, and this transcriptional repression by ICP22 is independent of the specific upstream promoter element, as shown using the CAT enzyme assay system. Further work also found that VP16 interfered with ICP22 mediated transcriptional repression of the viral α4 gene, through interactions with specific elements upstream of the α4 gene promoter. These findings support the possibility that ICP22 and VP16 control transcription of HSV1α genes in a common pathway for the establishment of either viral lytic or latent infections. | CUN Wei, GUO Lei, ZHANG Ying, LIU LongDing, WANG LiChun, LI JianFeng, DONG ChengHong, WANG JinJin & LI QiHan Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China | 2009 | Science China(Life Sciences)2009，52，4： | 4 |
| 3 | An integrated multi-energy flow calculation method for electricity-gas-thermal integrated energy systems显示文摘The modeling and multi-energy flow calculation of an integrated energy system (IES) are the bases of its operation and planning. This paper establishes the models of various energy sub-systems and the coupling equipment for an electricity-gas-thermal IES, and an integrated multi-energy flow calculation model of the IES is constructed. A simplified calculation method for the compressor model in a natural gas network, one which is not included in a loop and works in constant compression ratio mode, is also proposed based on the concept of model reduction. In addition, a numerical conversion method for dealing with the conflict between nominal value and per unit value in the multi-energy flow calculation of IES is described. A case study is given to verify the correctness and speed of the proposed method, and the electricity-gas-thermal coupling interaction characteristics among sub-systems are studied. | Mengting Zhu Chengsi Xu Shufeng Dong Kunjie Tang Chenghong Gu | 2021 | Protection and Control of Modern Power Systems2021，6，1： | 4 |
| 4 | Immediate-early gene product ICP22 inhibits the trans-transcription activating function of P53-mdm-2显示文摘As a product of HSVI immediate-early gene, ICP22 is capable of interacting with various cellular tran-scriptive and regulatory molecules during viral infection so as to impact the normal cellular molecular mechanism. ICP22 expressed in transfected cells can push the cells’ entering into S phase with binding to mdm-1 promoter region and impact its trans-transcription activating effect by P53. Consequently, the MDM-2 binds to P53, and the degradation effects by the ubiquitous pathway are decreased, improving indirectly the P53 levels in cells and making the cells progress into the S phase. | GUO HongXiong, CUN Wei, LIU LongDing, WANG LiChun, ZHAO HongLing, DONG ChengHong & LI QiHan Department of Viral Immunology, Institute of Medical Biology, CAMS and PUMC, Kunming 650118, China These authors contributed equally to this work | 2007 | Science China(Life Sciences)2007，50，4： | 2 |
| 5 | Atrial of arbidol hydrochloride in adults with COVID-19显示文摘Background: To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.Methods: This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.Results: A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled;66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64]vs. 42.4% [14/33];difference of conversion rate 27.9%;95% confidence interval [CI], 7.7%-48.1%;P=0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 daysvs. 12.0 days;hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060,P=0.006), symptom of fever (median 3.0 daysvs. 12.0 days;HR: 18.990, 95% CI: 5.350-67.410,P<0.001), as well as hospitalization (median 12.5 daysvs. 20.0 days;P<0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 daysvs. 14.5 days;P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression.Conclusions: SOC plus arbidol tablets significantly increase the negative conversion rate of SARS-CoV-2 within the first week and accelerate the recovery of COVID-19 patients. During the treatment with arbidol tablets, we find no significant serious adverse events. | Jingya Zhao Jinnong Zhang Yang Jin Zhouping Tang Ke Hu Hui Sun Mengmeng Shi Qingyuan Yang Peiyu Gu Hongrong Guo Qi Li Haiying Zhang Chenghong Li Ming Yang Nian Xiong Xuan Dong Juanjuan Xu Fan Lin Tao Wang Chao Yang Bo Huang Jingyi Zhang hi Chen Qiong He Min Zhou Jieming Qu | 2022 | Chinese Medical Journal2022，，13： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员